Potent antitumor activity of Cabozantinib, a c-MET and VEGFR2 Inhibitor, in a Colorectal Cancer Patient-derived Tumor Explant Model

Anti-angiogenic therapy is commonly used for the treatment of CRC. Although patients derive some clinical benefit, treatment resistance inevitably occurs. The MET signaling pathway has been proposed to be a major contributor of resistance to anti-angiogenic therapy. MET is upregulated in response to...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Cancer
Autori principali: Song, Eun-Kee, Tai, WM, Messersmith, Wells A., Bagby, Stacey, Purkey, Alicia, Quackenbush, Kevin S., Pitts, Todd M., Wang, Guoliang, Blatchford, Patrick, Yahn, Rachel, Kaplan, Jeffrey, Tan, Aik Choon, Atreya, Chloe E., Eckhardt, Gail, Kelley, Robin K., Venook, Alan, Kwak, Eunice L, Ryan, David, Arcaroli, John J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323738/
https://ncbi.nlm.nih.gov/pubmed/25242168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29225
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi